Special Issue

Cellular Immune Response to Hepatitis Viruses

Message from the Guest Editor

The liver maintains a delicate balance between immunological tolerance and the elimination of pathogens. Disruption of this balance can lead to hepatitis and severe complications. Besides classical hepatitis A–E viruses (HAV, HBV, HCV, HDV, HEV), various emerging and re-emerging agents, including yellow fever (YFV), dengue (DENV), Zika (ZIKV), Crimean–Congo hemorrhagic fever (CCHFV), Rift Valley fever (RVFV), Lassa (LASV), and Ebola (EBOV), also target the liver and contribute to the global burden of viral hepatitis. Understanding how these viruses interact with and evade immune responses is crucial for developing novel prophylactic and therapeutic strategies. This Special Issue, "Cellular Immune Response to Hepatitis Viruses," will focus on recent developments in viral sensing, immune evasion, immunopathology, immunomodulatory agents, and preclinical models for studying hepatotropic viruses. We invite submissions of original research, short communications, and review articles in this dynamic field. We look forward to your contributions.

Guest Editor

Dr. Armando Andres Roca Suarez

1. Inserm, UMR 1350 PaThLiv, Université Claude-Bernard Lyon 1, F-69003 Lyon, France
2. The Lyon Hepatology Institute, IHU EVEREST, F-69004 Lyon, France

Deadline for manuscript submissions

31 January 2026

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/249282

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/viruses

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/viruses

About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed
HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).